Patriot Financial Group Insurance Agency LLC bought a new stake in Intellia Therapeutics Inc (NASDAQ:NTLA) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 11,215 shares of the company’s stock, valued at approximately $165,000.
Other large investors have also recently modified their holdings of the company. Wells Fargo & Company MN boosted its position in shares of Intellia Therapeutics by 12.5% in the second quarter. Wells Fargo & Company MN now owns 52,214 shares of the company’s stock valued at $855,000 after acquiring an additional 5,802 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Intellia Therapeutics by 23.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,000 shares of the company’s stock valued at $152,000 after acquiring an additional 1,894 shares during the period. Bank of Montreal Can grew its holdings in shares of Intellia Therapeutics by 406.5% during the 2nd quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after purchasing an additional 3,069 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Intellia Therapeutics by 7.2% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 196,210 shares of the company’s stock worth $3,212,000 after purchasing an additional 13,205 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Intellia Therapeutics by 17.8% in the second quarter. Bank of New York Mellon Corp now owns 148,132 shares of the company’s stock worth $2,425,000 after purchasing an additional 22,386 shares during the period. Institutional investors and hedge funds own 90.18% of the company’s stock.
A number of research analysts recently commented on NTLA shares. ValuEngine downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 5th. BidaskClub lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Chardan Capital restated a “buy” rating and issued a $57.50 target price on shares of Intellia Therapeutics in a research report on Thursday, January 9th. Raymond James raised shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price target for the company in a report on Friday, November 1st. Finally, Zacks Investment Research lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. Intellia Therapeutics presently has an average rating of “Buy” and an average target price of $25.21.
NASDAQ:NTLA opened at $14.21 on Friday. Intellia Therapeutics Inc has a twelve month low of $10.26 and a twelve month high of $19.00. The company has a quick ratio of 7.89, a current ratio of 7.89 and a debt-to-equity ratio of 0.05. The stock’s 50-day simple moving average is $15.45 and its 200 day simple moving average is $14.90. The firm has a market capitalization of $696.05 million, a PE ratio of -7.21 and a beta of 2.77.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, October 31st. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.12. Intellia Therapeutics had a negative net margin of 225.54% and a negative return on equity of 33.00%. The firm had revenue of $10.60 million during the quarter, compared to analysts’ expectations of $9.17 million. During the same quarter in the prior year, the business earned ($0.53) earnings per share. The business’s revenue for the quarter was up 43.2% compared to the same quarter last year. On average, analysts anticipate that Intellia Therapeutics Inc will post -2.06 EPS for the current fiscal year.
Intellia Therapeutics Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Read More: Stock Portfolio Tracker
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.